Rachel Upthegrove

Rachel Upthegrove

Auto-generated profile, based on publicly available information

Rachel Upthegrove

University of Oxford

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2022 in The Lancet
Verified
Journal Article
Closed access
SMSteven Marwaha
Steven Marwaha
EPEdward Palmer
Edward Palmer
TSTrisha Suppes
Trisha Suppes
ECEmily Cons
Emily Cons
AYAllan H Young
Allan H Young
RURachel Upthegrove
Rachel Upthegrove

1 May 2014 in Schizophrenia Research
Verified
Journal Article
Closed access
RURachel Upthegrove
Rachel Upthegrove
NMNuria Manzanares-Teson
Nuria Manzanares-Teson
NBNicholas M. Barnes
Nicholas M. Barnes

1 November 2018 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
NKNikolaos Koutsouleris
Nikolaos Koutsouleris
LKLana Kambeitz-Ilankovic
Lana Kambeitz-Ilankovic
SRStephan Ruhrmann
Stephan Ruhrmann
MRMarlene Rosen
Marlene Rosen
ARAnne Ruef
Anne Ruef
FCfor the PRONIA Consortium
for the PRONIA Consortium
Recent research has extended the scope of early recognition and prevention of psychosis beyond disease transition to poor outcomes more broadly.1-5 This is because the clinical high-risk (CHR) state for psychosis, present in 2% to 10% of youth,6 may be linked with nonpsychotic morbidity encompassing mood, anxiety, and substance use disorders.3 Moreover, the CHR state frequently entails persistent neurocognitive and functional deficits, which may cause the affected young persons to increasingly lag behind their peers in a critical phase of personal development.7-9 Prospective research has demonstrated that these deficits, in combination with clinical and sociodemographic risk factors, foreshadow poor clinical outcomes.9-13 Similarly, adolescents and young adults who experience a first major affective episode are not only at risk for relapse but frequently have persistent functional deficits, depressive symptoms, and reduced quality of life, as is often seen in patients in the CHR state.14 These shared impairments6,15 may point to a common neurobiological surrogate predating the disabling outcomes of these conditions. Such a marker of brain pathology could accurately estimate the risk for functional deficits, thus informing risk-adapted preventive interventions in these vulnerable persons.

30 March 2022 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
JWJohn A. Williams
John A. Williams
SBStephen Burgess
Stephen Burgess
JSJohn Suckling
John Suckling
PLParis Alexandros Lalousis
Paris Alexandros Lalousis
FBFatima Batool
Fatima Batool
NHNeil Harrison
Neil Harrison
Numerous avenues of inquiry suggest a relationship between immune dysfunction and psychiatric disorders, including schizophrenia, autism spectrum disorders, and depression.1 There is robust evidence for increased circulating concentrations of proinflammatory cytokines before the onset of illness,2 and epidemiological studies have shown that exposure to a variety of infections during prenatal life and childhood are associated with increased risk of schizophrenia and autism spectrum disorder.3-5 Recent analyses using mendelian randomization (MR) suggest potential causality between inflammatory cytokines and schizophrenia and depression.6 This background supports theories of maternal immune activation of early inflammatory processes and a 2-hit model with subsequent environmental factors triggering nonresolving inflammation and the precipitation of psychiatric disorders.7-10

20 August 2018 in Early Intervention in Psychiatry
Verified
Journal Article
Closed access
PDF file
ASAlexandra Stainton
Alexandra Stainton
KCKatharine Chisholm
Katharine Chisholm
NKNathalie Kaiser
Nathalie Kaiser
MRMarlene Rosen
Marlene Rosen
RURachel Upthegrove
Rachel Upthegrove
SWStephen J. Wood
Stephen J. Wood

15 July 2016 in Schizophrenia Bulletin
Verified
Journal Article
Open access
PDF file
RURachel Upthegrove
Rachel Upthegrove
SMSteven Marwaha
Steven Marwaha
MBMax Birchwood
Max Birchwood
The presence of depression in schizophrenia has been a challenge to the Kraepelinian dichotomy, with various attempts to save the fundamental distinction including evoking and refining diagnoses such as schizoaffective disorder. But the tectonic plates are shifting. Here we put forward a summary of recent evidence regarding the prevalence, importance, possible aetiological pathways and treatment challenges that recognizing depression in schizophrenia bring. Taken together we propose that depression is more than comorbidity and that increased effective therapeutic attention to mood symptoms will be needed to improve outcomes and to support prevention.